Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events

Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Imafuku, Keisuke, Yoshino, Koji, Yamaguchi, Kei, Tsuboi, Satoshi, Ohara, Kuniaki, Hata, Hiroo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422733/
https://www.ncbi.nlm.nih.gov/pubmed/28512413
http://dx.doi.org/10.1159/000463379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422733/
https://www.ncbi.nlm.nih.gov/pubmed/28512413
http://dx.doi.org/10.1159/000463379

Ejemplares similares